Stem Cell Patent Case Will Be Early Test Of Myriad's Reach

Law360, New York (July 10, 2013, 8:55 PM EDT) -- A suit seeking to invalidate a patent on human embryonic stem cells could provide some early indication as to whether the U.S. Supreme Court's ruling that isolated DNA cannot be patented applies to other technology involving natural material, attorneys say.

Filed less than three weeks after the high court's decision, Consumer Watchdog's appeal to the Federal Circuit argues that a stem cell patent held by the Wisconsin Alumni Research Foundation is a product of nature that is not eligible for a patent, like Myriad Genetics Inc.'s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.